abstract: In 1985, @entity5 and @entity1778 Group B initiated a multi-institutional study to define the role of interferon alpha in therapy of previously untreated active @entity5734 ( @entity5734 ). This is a long-term follow-up report of the study. Fifty-five evaluable @entity1 were treated with recombinant interferon-2b 2 million units/m2 subcutaneously three times a week for 1 year. Treatment was well tolerated; @entity137 mainly consisted of @entity683 and @entity3043 , both of a transient nature. Seventy-three percent of @entity1 had objective beneficial responses with 8.3 months median time to achieve at least a partial response (PR). After 1 year of therapy, the @entity1 have been observed for a median of 5 years. There was a continual trend towards relapse throughout this period but 28% have remained in remission beyond 6 years. Forty-six @entity1 (83%) are alive at 6 years. Among the 40 @entity1 who achieved at least a PR, there were 28 with @entity381 at the beginning of study: the spleen size was reduced in all with interferon alpha therapy and none required splenectomy. This study confirms the results of other investigators, and demonstrates that recombinant alpha interferon-2b is an effective agent for treatment of @entity5734 .

title: Recombinant alpha-2b-interferon in therapy of previously untreated @entity5734 : long-term follow-up results of study by @entity5 and XXXX Group B.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity5734 :: ('MESH:D007943', 'Disease') :: ['HCL', 'hairy cell leukemia']

entities_list: @entity683 :: ('MESH:D007251', 'Disease') :: ['flu-like syndrome']

entities_list: @entity381 :: ('MESH:D013163', 'Disease') :: ['splenomegaly']

entities_list: @entity3043 :: ('MESH:D010198', 'Disease') :: ['pancytopenia']

answer: @entity1778 :: (MESH:D007938,Disease) :: ['Leukemia']


abstract: In 1985, @entity5 and @entity1778 Group B initiated a multi-institutional study to define the role of interferon alpha in therapy of previously untreated active @entity5734 ( @entity5734 ). This is a long-term follow-up report of the study. Fifty-five evaluable @entity1 were treated with recombinant interferon-2b 2 million units/m2 subcutaneously three times a week for 1 year. Treatment was well tolerated; @entity137 mainly consisted of @entity683 and @entity3043 , both of a transient nature. Seventy-three percent of @entity1 had objective beneficial responses with 8.3 months median time to achieve at least a partial response (PR). After 1 year of therapy, the @entity1 have been observed for a median of 5 years. There was a continual trend towards relapse throughout this period but 28% have remained in remission beyond 6 years. Forty-six @entity1 (83%) are alive at 6 years. Among the 40 @entity1 who achieved at least a PR, there were 28 with @entity381 at the beginning of study: the spleen size was reduced in all with interferon alpha therapy and none required splenectomy. This study confirms the results of other investigators, and demonstrates that recombinant alpha interferon-2b is an effective agent for treatment of @entity5734 .

title: Recombinant alpha-2b-interferon in therapy of previously untreated @entity5734 : long-term follow-up results of study by XXXX and @entity1778 Group B.

answer: @entity5 :: (MESH:D009369,Disease) :: ['Cancer']


abstract: In 1985, @entity5 and @entity1778 Group B initiated a multi-institutional study to define the role of interferon alpha in therapy of previously untreated active @entity5734 ( @entity5734 ). This is a long-term follow-up report of the study. Fifty-five evaluable @entity1 were treated with recombinant interferon-2b 2 million units/m2 subcutaneously three times a week for 1 year. Treatment was well tolerated; @entity137 mainly consisted of @entity683 and @entity3043 , both of a transient nature. Seventy-three percent of @entity1 had objective beneficial responses with 8.3 months median time to achieve at least a partial response (PR). After 1 year of therapy, the @entity1 have been observed for a median of 5 years. There was a continual trend towards relapse throughout this period but 28% have remained in remission beyond 6 years. Forty-six @entity1 (83%) are alive at 6 years. Among the 40 @entity1 who achieved at least a PR, there were 28 with @entity381 at the beginning of study: the spleen size was reduced in all with interferon alpha therapy and none required splenectomy. This study confirms the results of other investigators, and demonstrates that recombinant alpha interferon-2b is an effective agent for treatment of @entity5734 .

title: Recombinant alpha-2b-interferon in therapy of previously untreated XXXX : long-term follow-up results of study by @entity5 and @entity1778 Group B.

answer: @entity5734 :: (MESH:D007943,Disease) :: ['hairy cell leukemia']


abstract: Recent advances in immunology and histological techniques suggest that besides humoral also cellular mechanisms participate in the development of @entity8 . The purpose of this study was to examine whether @entity1 with @entity8 or @entity631 ( @entity631 ) show a disturbance of the immunoregulatory system in the light of peripheral T lymphocyte subset analysis. Mononuclear leukocytes were analysed with monoclonal antibodies (OKT 11, 4 and 8, OKM 1, @entity4755 ). Two categories of findings, depending on the clinical picture, were obtained in both types of @entity1310 . Of 16 @entity8 @entity1 , eight with more serious clinical symptoms had a significantly lower OKT4/OKT8 ratio (mean +/- s.d.: 1.13 +/- 0.37) than controls, p less than 0.01. This was mainly due to an increase of @entity19 positive cells. @entity1 with a mild clinical picture had a normal OKT4/OKT8 ratio. An equally low OKT4/OKT8 ratio (1.22 +/- 0.44) was observed in seven @entity631 @entity1 with @entity1985 range @entity644 . Some of the @entity1 with a high percentage of @entity19 positive cells had a high percentage of @entity4755 positive cells, too. These results suggest disturbed immunoregulation in a group of @entity1 with @entity8 or @entity631 . However, @entity3450 may have influenced results in the @entity631 group. The cause and prognostic significance of the decreased OKT4/OKT8 ratio is uncertain at the present time.

title: Immunological mechanisms in @entity631 . A short review and analysis of peripheral mononuclear cell subsets in XXXX and @entity631 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity1310 :: ('MESH:D009393', 'Disease') :: ['nephritis']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['IgA nephropathy', 'glomerular disease']

entities_list: @entity3450 :: ('MESH:D009401', 'Disease') :: ['nephrosis']

entities_list: @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['membranous glomerulonephritis', 'MGN']

answer: @entity8 :: (MESH:D007674,Disease) :: ['IgA nephropathy']


abstract: Recent advances in immunology and histological techniques suggest that besides humoral also cellular mechanisms participate in the development of @entity8 . The purpose of this study was to examine whether @entity1 with @entity8 or @entity631 ( @entity631 ) show a disturbance of the immunoregulatory system in the light of peripheral T lymphocyte subset analysis. Mononuclear leukocytes were analysed with monoclonal antibodies (OKT 11, 4 and 8, OKM 1, @entity4755 ). Two categories of findings, depending on the clinical picture, were obtained in both types of @entity1310 . Of 16 @entity8 @entity1 , eight with more serious clinical symptoms had a significantly lower OKT4/OKT8 ratio (mean +/- s.d.: 1.13 +/- 0.37) than controls, p less than 0.01. This was mainly due to an increase of @entity19 positive cells. @entity1 with a mild clinical picture had a normal OKT4/OKT8 ratio. An equally low OKT4/OKT8 ratio (1.22 +/- 0.44) was observed in seven @entity631 @entity1 with @entity1985 range @entity644 . Some of the @entity1 with a high percentage of @entity19 positive cells had a high percentage of @entity4755 positive cells, too. These results suggest disturbed immunoregulation in a group of @entity1 with @entity8 or @entity631 . However, @entity3450 may have influenced results in the @entity631 group. The cause and prognostic significance of the decreased OKT4/OKT8 ratio is uncertain at the present time.

title: Immunological mechanisms in XXXX . A short review and analysis of peripheral mononuclear cell subsets in @entity8 and @entity631 .

answer: @entity631 :: (MESH:D005921,Disease) :: ['glomerulonephritis']


abstract: Recent advances in immunology and histological techniques suggest that besides humoral also cellular mechanisms participate in the development of @entity8 . The purpose of this study was to examine whether @entity1 with @entity8 or @entity631 ( @entity631 ) show a disturbance of the immunoregulatory system in the light of peripheral T lymphocyte subset analysis. Mononuclear leukocytes were analysed with monoclonal antibodies (OKT 11, 4 and 8, OKM 1, @entity4755 ). Two categories of findings, depending on the clinical picture, were obtained in both types of @entity1310 . Of 16 @entity8 @entity1 , eight with more serious clinical symptoms had a significantly lower OKT4/OKT8 ratio (mean +/- s.d.: 1.13 +/- 0.37) than controls, p less than 0.01. This was mainly due to an increase of @entity19 positive cells. @entity1 with a mild clinical picture had a normal OKT4/OKT8 ratio. An equally low OKT4/OKT8 ratio (1.22 +/- 0.44) was observed in seven @entity631 @entity1 with @entity1985 range @entity644 . Some of the @entity1 with a high percentage of @entity19 positive cells had a high percentage of @entity4755 positive cells, too. These results suggest disturbed immunoregulation in a group of @entity1 with @entity8 or @entity631 . However, @entity3450 may have influenced results in the @entity631 group. The cause and prognostic significance of the decreased OKT4/OKT8 ratio is uncertain at the present time.

title: Immunological mechanisms in @entity631 . A short review and analysis of peripheral mononuclear cell subsets in @entity8 and XXXX .

answer: @entity631 :: (MESH:D005921,Disease) :: ['membranous glomerulonephritis']


abstract: To develop restriction enzymes that are useful for genome analysis, we previously performed screening and isolated Sse8387I from Streptomyces sp. strain 8387. Sse8387I is a restriction enzyme that recognizes 5'-CCTGCA/GG-3' and cleaves DNA at the site shown by the diagonal (Nucleic Acid Res., 18, 5637-5640). The present study evaluated the effects of methylation that is important when Sse8387I is used for genome analysis. Sse8387I lost cleavage activity after methylation of @entity5536 or methylation of @entity5538 at any site in the recognition sequence. However, the recognition sequence of Sse8387I contains no CG sequence, which is the @entity1 methylation sequence. In addition, we evaluated the effects of methylation of CG at sites other than the recognition sequence. The cleavage activity of Sse8387I was maintained even when CG sequences were present immediately before or after, or near the recognition sequence, and @entity5538 was methylated. These results suggest that CG methylation does not affect the cleavage activity of Sse8387I. Therefore, Sse8387I seems to be very useful for @entity1 genome analysis.

title: Sse8387I, a useful eight base cutter for XXXX genome analysis (influence of methylation on the activity of Sse8387I).

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity5538 :: ('MESH:D003596', 'Chemical') :: ['cytosine']

answer: @entity1 :: (9606,Species) :: ['mammalian']


abstract: UNASSIGNED: Despite extensive research over the years, there still exists some debate as to what constitutes the optimal therapeutic strategy to promote recovery following @entity64 . Due to the complexity of injured brain pathophysiology, treatment approaches should ideally address numerous factors, ultimately aiming to promote tissue protection, axonal regrowth and functional recovery. In this study we extend our understanding of the effects of bone marrow stromal cell (BMSC) treatment following experimentally induced @entity385 in @entity35 . Focal @entity2806 was experimentally induced in @entity35 by placing a preformed clot into the middle cerebral artery. Animals were injected intravenously with BMSCs at 24 hr after @entity64 and were sacrificed 7 days post injury. When administered BMSCs following @entity64 , neurological outcome was significantly improved relative to controls. There was an increase in the number of BMSCs labelled with BrdU present in the injured hemisphere of the brain compared to the non-injured side. Furthermore, administration of BMSCs also led to increases in @entity5219 , vascularization and endogenous proliferation. These findings provide insight into the mechanisms of action of BMSC treatment and further argue for the therapeutic potential of BMSCs as an effective treatment following @entity64 . This article is protected by copyright. All rights reserved.

title: Multipotent Bone Marrow Stromal Cell Therapy Promotes Endogenous Cell Proliferation Following XXXX .

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'cerebral stroke']

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['ischemic brain injury']

entities_list: @entity5219 :: ('MESH:D005911', 'Disease') :: ['astrocytosis']

entities_list: @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']

answer: @entity385 :: (MESH:D002544,Disease) :: ['Ischemic Stroke']


abstract: BACKGROUND:: There is a theoretical concern that a @entity715 may be dislodged distally when crossing the occluded segment during recanalization of a complete occlusion. OBJECTIVE:: To assess the immediate post-procedural brain diffusion weighted image (DWI) findings following endovascular recanalization using an embolic protection device for proximal internal carotid artery ( @entity6455 ) occlusion. MATERIALS AND METHODS:: We retrospectively identified 12 @entity1 who underwent stent implantation for sudden symptomatic occlusion of the proximal @entity6455 . In 8 @entity1 , no additional intracranial occlusions were identified. In 4 @entity1 , an additional intracerebral @entity715 was detected in the middle cerebral artery (MCA). Distal protection devices were used in all cases. We evaluated the presence and amount of retrieved @entity887 in the distal protection devices. The incidence and location of @entity12870 were determined using DWI. RESULTS:: Recanalization of the proximal @entity6455 was achieved in all @entity1 . After complete occlusion of the proximal @entity6455 was demonstrated, primary passage of the embolic protection device through the occluded @entity6455 was gently navigated in 7 @entity1 . However, this was not possible in 5 @entity1 . 3 @entity1 developed new lesions on post-procedural DWI. Of the 12 @entity1 in which distal protection devices were used, debris was detected in 7 @entity1 . CONCLUSION:: In endovascular revascularization of proximal @entity6455 occlusion, @entity12870 occur less frequently than reported in a systematic review of the DWI literature. The real risk of dislodging thrombi appears to be from plaque fragment mobilization by angioplasty, rather than crossing an occluded segment.

title: What is the real risk of dislodging thrombi during endovascular revascularization of a proximal XXXX occlusion?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity887 :: ('MESH:D004617', 'Disease') :: ['embolic fragments']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']

entities_list: @entity12870 :: ('MESH:D055191', 'Disease') :: ['post-procedural emboli']

answer: @entity6455 :: (CHEBI:29202,Chemical) :: ['ICA']


abstract: BACKGROUND: When identifying clinical markers predicting clinical outcome, disease recurrence and resistance to therapies often determine the diagnosis and therapy of some @entity5 types. OBJECTIVE: To investigate whether @entity28333 positive expression is an indicator of prognosis in @entity1 with @entity463 . METHODS: Forty-seven @entity1 treated with surgery, radiotherapy, and adjuvant chemotherapy between 2005 and 2007 were divided into 2 groups according to @entity28333 expression in an immunohistochemical study: the @entity28333 negative group (n = 12 @entity1 ) and the @entity28333 positive group (n = 35 @entity1 ). The clinicopathologic features and survival data for @entity1 in the @entity28333 positive group were compared with data from the @entity1 in the @entity28333 negative group. Kaplan-Meier survival analysis and univariate and multivariate analyses were performed to determine the prognostic factors that influenced @entity1 survival. RESULTS: @entity28333 positive expression was observed in approximately 74.5% of @entity1 with @entity463 . @entity1 in the @entity28333 positive group had lower overall survival rates and median survival time than those in the @entity28333 negative group (overall 2-year actuarial survival rates, 8.6% for the @entity28333 positive group vs 16.7% for the @entity28333 negative group; overall 2-year median survival time, 12.9 months for the @entity28333 positive group vs 17.9 months for the @entity28333 negative group, P = .019). @entity28333 positive expression in @entity5 cells also was correlated with a shorter interval to @entity5 recurrence (median interval to recurrence, 5.9 months in the @entity28333 positive group vs 8.3 months in the @entity28333 negative group, P = .002). Univariate and multivariate analyses showed that @entity28333 positive expression was an independent prognostic factor. CONCLUSION: @entity28333 positive expression can be used as a potential molecular risk factor in @entity1 with @entity463 .

title: 14-3-3   positive expression is associated with a poor prognosis in @entity1 with XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma']

answer: @entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']


abstract: BACKGROUND: When identifying clinical markers predicting clinical outcome, disease recurrence and resistance to therapies often determine the diagnosis and therapy of some @entity5 types. OBJECTIVE: To investigate whether @entity28333 positive expression is an indicator of prognosis in @entity1 with @entity463 . METHODS: Forty-seven @entity1 treated with surgery, radiotherapy, and adjuvant chemotherapy between 2005 and 2007 were divided into 2 groups according to @entity28333 expression in an immunohistochemical study: the @entity28333 negative group (n = 12 @entity1 ) and the @entity28333 positive group (n = 35 @entity1 ). The clinicopathologic features and survival data for @entity1 in the @entity28333 positive group were compared with data from the @entity1 in the @entity28333 negative group. Kaplan-Meier survival analysis and univariate and multivariate analyses were performed to determine the prognostic factors that influenced @entity1 survival. RESULTS: @entity28333 positive expression was observed in approximately 74.5% of @entity1 with @entity463 . @entity1 in the @entity28333 positive group had lower overall survival rates and median survival time than those in the @entity28333 negative group (overall 2-year actuarial survival rates, 8.6% for the @entity28333 positive group vs 16.7% for the @entity28333 negative group; overall 2-year median survival time, 12.9 months for the @entity28333 positive group vs 17.9 months for the @entity28333 negative group, P = .019). @entity28333 positive expression in @entity5 cells also was correlated with a shorter interval to @entity5 recurrence (median interval to recurrence, 5.9 months in the @entity28333 positive group vs 8.3 months in the @entity28333 negative group, P = .002). Univariate and multivariate analyses showed that @entity28333 positive expression was an independent prognostic factor. CONCLUSION: @entity28333 positive expression can be used as a potential molecular risk factor in @entity1 with @entity463 .

title: 14-3-3   positive expression is associated with a poor prognosis in XXXX with @entity463 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: To describe the clinical features and management of extensive ocular surface @entity5 (OSSN) ( @entity957 ) of the socket. METHODS: Retrospective interventional case series. Interferon a 2b ( @entity4020 ) eye drops (1 million units/cc) 4 times daily and @entity4020 sublesional injection (5 million units/0.5cc to 8 million units/0.8 cc) were delivered for @entity5 control. @entity1 were 3 @entity1 with ocular prosthesis who developed extensive socket OSSN. Tumor control was graded as complete regression, partial regression, or no regression. RESULTS: OSSN was detected in the socket at age 60, 43, and 20 years in @entity1 who had worn ophthalmic prostheses for 54, 26, and 13 years, respectively. The @entity1 had chronic discharge and @entity146 (n = 3) managed with intermittent topical corticosteroids (n = 2). There were no predisposing factors of cigarette exposure, radiation exposure, @entity484 , @entity1200 , or organ transplantation. The prosthesis fit well with nonirritative edges. At presentation, OSSN was subtle (n = 3), vascular (n = 3), and multifocal (n = 3), with largest lesions or confluence of lesions measuring 20, 25, and 20 mm, respectively. The @entity5 involved the tarsal (n = 3), bulbar (n = 2), and forniceal (n = 2) surfaces. All @entity1 were treated with topical and injection @entity4020 , with complete regression achieved in 2 cases (at 1 months and 20 months) and partial regression in one case (at 9 months). All @entity1 continue on chronic maintenance @entity4020 topically. There were no recurrences, and @entity4020 injection side effects of @entity390 and chills were minor, lasting 1 day. No @entity1 required surgical removal of @entity5 from the socket and no @entity1 required exenteration. CONCLUSIONS: @entity1 wearing ophthalmic prosthesis over a socket should be monitored for the development of OSSN. Combined topical and injection @entity4020 could represent a potentially effective therapy for this condition.

title: Ocular surface @entity5 ( XXXX ) of the socket: management of extensive @entity5 with interferon.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Participants']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['irritation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'squamous neoplasia', 'tumors']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma']

entities_list: @entity1200 :: ('MESH:D007154', 'Disease') :: ['systemic immune suppression']

answer: @entity957 :: (MESH:D002294,Disease) :: ['squamous cell carcinoma']


abstract: PURPOSE: To describe the clinical features and management of extensive ocular surface @entity5 (OSSN) ( @entity957 ) of the socket. METHODS: Retrospective interventional case series. Interferon a 2b ( @entity4020 ) eye drops (1 million units/cc) 4 times daily and @entity4020 sublesional injection (5 million units/0.5cc to 8 million units/0.8 cc) were delivered for @entity5 control. @entity1 were 3 @entity1 with ocular prosthesis who developed extensive socket OSSN. Tumor control was graded as complete regression, partial regression, or no regression. RESULTS: OSSN was detected in the socket at age 60, 43, and 20 years in @entity1 who had worn ophthalmic prostheses for 54, 26, and 13 years, respectively. The @entity1 had chronic discharge and @entity146 (n = 3) managed with intermittent topical corticosteroids (n = 2). There were no predisposing factors of cigarette exposure, radiation exposure, @entity484 , @entity1200 , or organ transplantation. The prosthesis fit well with nonirritative edges. At presentation, OSSN was subtle (n = 3), vascular (n = 3), and multifocal (n = 3), with largest lesions or confluence of lesions measuring 20, 25, and 20 mm, respectively. The @entity5 involved the tarsal (n = 3), bulbar (n = 2), and forniceal (n = 2) surfaces. All @entity1 were treated with topical and injection @entity4020 , with complete regression achieved in 2 cases (at 1 months and 20 months) and partial regression in one case (at 9 months). All @entity1 continue on chronic maintenance @entity4020 topically. There were no recurrences, and @entity4020 injection side effects of @entity390 and chills were minor, lasting 1 day. No @entity1 required surgical removal of @entity5 from the socket and no @entity1 required exenteration. CONCLUSIONS: @entity1 wearing ophthalmic prosthesis over a socket should be monitored for the development of OSSN. Combined topical and injection @entity4020 could represent a potentially effective therapy for this condition.

title: Ocular surface XXXX ( @entity957 ) of the socket: management of extensive @entity5 with interferon.

answer: @entity5 :: (MESH:D009369,Disease) :: ['squamous neoplasia']


abstract: PURPOSE: To describe the clinical features and management of extensive ocular surface @entity5 (OSSN) ( @entity957 ) of the socket. METHODS: Retrospective interventional case series. Interferon a 2b ( @entity4020 ) eye drops (1 million units/cc) 4 times daily and @entity4020 sublesional injection (5 million units/0.5cc to 8 million units/0.8 cc) were delivered for @entity5 control. @entity1 were 3 @entity1 with ocular prosthesis who developed extensive socket OSSN. Tumor control was graded as complete regression, partial regression, or no regression. RESULTS: OSSN was detected in the socket at age 60, 43, and 20 years in @entity1 who had worn ophthalmic prostheses for 54, 26, and 13 years, respectively. The @entity1 had chronic discharge and @entity146 (n = 3) managed with intermittent topical corticosteroids (n = 2). There were no predisposing factors of cigarette exposure, radiation exposure, @entity484 , @entity1200 , or organ transplantation. The prosthesis fit well with nonirritative edges. At presentation, OSSN was subtle (n = 3), vascular (n = 3), and multifocal (n = 3), with largest lesions or confluence of lesions measuring 20, 25, and 20 mm, respectively. The @entity5 involved the tarsal (n = 3), bulbar (n = 2), and forniceal (n = 2) surfaces. All @entity1 were treated with topical and injection @entity4020 , with complete regression achieved in 2 cases (at 1 months and 20 months) and partial regression in one case (at 9 months). All @entity1 continue on chronic maintenance @entity4020 topically. There were no recurrences, and @entity4020 injection side effects of @entity390 and chills were minor, lasting 1 day. No @entity1 required surgical removal of @entity5 from the socket and no @entity1 required exenteration. CONCLUSIONS: @entity1 wearing ophthalmic prosthesis over a socket should be monitored for the development of OSSN. Combined topical and injection @entity4020 could represent a potentially effective therapy for this condition.

title: Ocular surface @entity5 ( @entity957 ) of the socket: management of extensive XXXX with interferon.

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumors']


abstract: Stereotactic adrenal medullary transplantation into the striatum was performed in 5 @entity1 with severe @entity191 . Four @entity1 had previously been treated with thalamotomies and all were on L-dopa therapy with significant side effects. All 5 @entity1 had shown marked disability before the procedure. Autologous adrenal medullary tissue was sliced into 20-30 fragments and transplanted into two sites of the caudate nucleus, one at the ventricular surface and the other in the head of the nucleus. The cases were followed for 4-5 years (mean 4.5 years), except for 1 @entity1 who died of unrelated causes 22 months after the procedure. Initial bilateral symptom improvement was observed in all cases for 9-21 months (mean 15.2 months) after transplantation without L-dopa therapy. Later, these improvements progressively deteriorated. L-dopa therapy had to be resumed for all. MRI on the long-term follow-up showed the transplanted tissue as a low signal intensity area surrounded by high intensity spots in T1- and T2-weighted images. Compared to previous MR studies, the transplanted tissue was shrunken and presumed nonviable.

title: Long-term follow-up results of stereotactic adrenal medullary transplantation in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease"]

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's disease']


abstract: PURPOSE: To identify factors influencing visual outcomes in @entity1 with @entity5861 (MA). METHODS: We retrospectively reviewed the charts of 13 eyes of 13 @entity1 with @entity548 MAs. We evaluated factors. including age, blood pressure, ocular perfusion pressure, optic disc-MA distance, MA-fovea distance, the area of the @entity548 , the time between onset and treatment, initial visual acuity, and the presence of @entity548 . Additionally, we measured the retinal cross-sectional area of the fovea with optical coherence tomography (OCT). RESULTS: There were significant differences in MA-fovea distance, area of the @entity548 , and visual outcome in eyes with or without @entity548 (p < 0.05). Spearman's correlation analysis showed a significant negative correlation between visual outcome (logMAR) and disc-MA distance (rS = -0.61, p < 0.05), as well as MA-fovea distance (rS = -0.79, p < 0.01). A multivariate analysis showed an independent negative correlation between visual outcome and MA-fovea distance (Stdb = -0.66, t = 3.21, p < 0.01). In addition, there was a significant positive correlation between MA-fovea distance and the affected-/healthy-eye ratio of outer-retinal-layer cross-sectional area in the fovea (rS = 0.64, p < 0.05). The cutoff value of MA-fovea distance for @entity548 was 3000 microns, with a sensitivity of 100, specificity of 77.8, positive predictive value of 66.7 and a negative predictive value of 100. CONCLUSIONS: When @entity548 MAs are located closer to the fovea, the outer retinal layer is more severely affected and visual outcomes are poorer. @entity548 should be considered even when it is not apparent, especially when the @entity548 MA is located within 3000 microns of the fovea.

title: [Clinical Research of Factors Influencing Visual Outcomes in @entity1 with XXXX ].

entities_list: @entity5861 :: ('MESH:D012166', 'Disease') :: ['hemorrhagic retinal arterial macroaneurysms']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhagic', 'subretinal hemorrhage', 'hemorrhage', 'Subfoveal hemorrhage', 'subfoveal hemorrhage']

answer: @entity5861 :: (MESH:D012166,Disease) :: ['Hemorrhagic Retinal Arterial Macroaneurysms']


abstract: PURPOSE: To identify factors influencing visual outcomes in @entity1 with @entity5861 (MA). METHODS: We retrospectively reviewed the charts of 13 eyes of 13 @entity1 with @entity548 MAs. We evaluated factors. including age, blood pressure, ocular perfusion pressure, optic disc-MA distance, MA-fovea distance, the area of the @entity548 , the time between onset and treatment, initial visual acuity, and the presence of @entity548 . Additionally, we measured the retinal cross-sectional area of the fovea with optical coherence tomography (OCT). RESULTS: There were significant differences in MA-fovea distance, area of the @entity548 , and visual outcome in eyes with or without @entity548 (p < 0.05). Spearman's correlation analysis showed a significant negative correlation between visual outcome (logMAR) and disc-MA distance (rS = -0.61, p < 0.05), as well as MA-fovea distance (rS = -0.79, p < 0.01). A multivariate analysis showed an independent negative correlation between visual outcome and MA-fovea distance (Stdb = -0.66, t = 3.21, p < 0.01). In addition, there was a significant positive correlation between MA-fovea distance and the affected-/healthy-eye ratio of outer-retinal-layer cross-sectional area in the fovea (rS = 0.64, p < 0.05). The cutoff value of MA-fovea distance for @entity548 was 3000 microns, with a sensitivity of 100, specificity of 77.8, positive predictive value of 66.7 and a negative predictive value of 100. CONCLUSIONS: When @entity548 MAs are located closer to the fovea, the outer retinal layer is more severely affected and visual outcomes are poorer. @entity548 should be considered even when it is not apparent, especially when the @entity548 MA is located within 3000 microns of the fovea.

title: [Clinical Research of Factors Influencing Visual Outcomes in XXXX with @entity5861 ].

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: We carried out sonographic examination of 160 type I @entity6 measuring the renal volume, the parenchyma/renal pelvis index and the brightness of the parenchyma. @entity1011 and @entity2262 in the serum, @entity1011 clearance and albumin excretion by urine were determined as functional parameters. In contrast to existing results, we were unable to find significant changes in kidney size or function in newly diagnosed @entity6 (duration of @entity6 up to 6 months). Both the @entity8 were unchanged compared to control @entity1 of the same age. It was only if @entity6 lasted from 6 months to 5 years, that the renal volume was 19% larger (192 +/- 37 cm3/1.73 m2) than that of recently diagnosed @entity1 (p less than 0.01). The index had increased by 15%, whereas the @entity1011 clearance had increased by 18% to 121 +/- 27 ml/min as a result of increased perfusion. The renal volume decreased continuously over a five-year period of duration of @entity6 . Initially, microalbuminuria became manifest, followed some time later by a decrease in @entity1011 clearance and a corresponding increase in @entity1011 and @entity2262 in serum. No change in parenchyma brightness was noted. @entity6 with moderate @entity177 ( @entity1011 1.2 to 2 mg/dl) compared to @entity6 without insufficiency developed larger kidneys (207 cm3/1.73 m2; p less than 0.01). Only in case of severe insufficiency ( @entity1011 greater than 2 mg/dl) did the kidneys did shrink significantly (121 cm3/1,73 m2, n = 8, p less than 0.01). The temporary enlargement of the kidneys could be a prognostically unfavourable sign pointing towards a developing @entity2316 .

title: [Sonographic changes in the size of the kidneys in type I diabetes as a method of early detection of XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'persons']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['parenchyma/renal pelvis index and the kidney parenchyma']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetics', 'Diabetics', 'diabetes']

entities_list: @entity2316 :: ('MESH:D003928', 'Disease') :: ['diabetic nephropathy']

entities_list: @entity2262 :: ('567', 'Gene') :: ['beta-2-microglobulin']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['Creatinine', 'creatinine']

answer: @entity2316 :: (MESH:D003928,Disease) :: ['diabetic nephropathy']


abstract: Hyperactivity of the subthalamic nucleus (STN) is major characteristic of @entity304 secondary to substantia nigra lesions. Interruption of the STN-internal pallidum (GPi) pathway is a new stereotactic target for @entity191 . We have studied the antiparkinsonian efficacy of STN lesions in @entity5212 -treated monkeys. Four @entity2608 were made @entity191 by @entity5212 (i.v. 0.15 +/- 1 mg/kg) administration over 3 months. Unilateral subthalamotomy ( @entity4176 ) was performed by a standard stereotactic method. Severity was rated from 0 (normal) to V by fine manual motor tests. Three monkeys (severity state III/IV) showed marked improvement in spontaneous activity, facial expression and manual dexterity bilaterally but significantly greater in the limb contralateral to the lesion. Mild hemichorea was present in 2 and hemiballism in one. L-Dopa treatment (50 mg b.i.d.) enhanced the hemidyskinesias moderately. The therapeutic effect has persisted for over 8 months postsurgery. Monkey No.4 (severity stage V) showed @entity4790 in the lower limb contralateral to the lesion but no improvement and died a few days later. Subthalamotomy improves @entity304 in moderately severe @entity191 monkeys. @entity910 might be a persistent complication.

title: Subthalamotomy improves XXXX -induced @entity304 in monkeys.

entities_list: @entity304 :: ('MESH:D010302', 'Disease') :: ['parkinsonism']

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['Dyskinesia']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'parkinsonian']

entities_list: @entity4176 :: ('MESH:D007608', 'Chemical') :: ['kainic acid']

entities_list: @entity2608 :: ('9544', 'Species') :: ['rhesus monkeys']

answer: @entity5212 :: (MESH:D015632,Chemical) :: ['MPTP']


abstract: Hyperactivity of the subthalamic nucleus (STN) is major characteristic of @entity304 secondary to substantia nigra lesions. Interruption of the STN-internal pallidum (GPi) pathway is a new stereotactic target for @entity191 . We have studied the antiparkinsonian efficacy of STN lesions in @entity5212 -treated monkeys. Four @entity2608 were made @entity191 by @entity5212 (i.v. 0.15 +/- 1 mg/kg) administration over 3 months. Unilateral subthalamotomy ( @entity4176 ) was performed by a standard stereotactic method. Severity was rated from 0 (normal) to V by fine manual motor tests. Three monkeys (severity state III/IV) showed marked improvement in spontaneous activity, facial expression and manual dexterity bilaterally but significantly greater in the limb contralateral to the lesion. Mild hemichorea was present in 2 and hemiballism in one. L-Dopa treatment (50 mg b.i.d.) enhanced the hemidyskinesias moderately. The therapeutic effect has persisted for over 8 months postsurgery. Monkey No.4 (severity stage V) showed @entity4790 in the lower limb contralateral to the lesion but no improvement and died a few days later. Subthalamotomy improves @entity304 in moderately severe @entity191 monkeys. @entity910 might be a persistent complication.

title: Subthalamotomy improves @entity5212 -induced XXXX in monkeys.

answer: @entity304 :: (MESH:D010302,Disease) :: ['parkinsonism']


abstract: INTRODUCTION: @entity6794 is a rare, chronic, destructive, ulcerating skin disease of uncertain etiology. It develops most frequently in @entity1 between 25-45 years of age and affects both sexes equally. CASE REPORT: We present a case of @entity6794 in a young female @entity1 who sustained a burn injury of 40% total body surface area. She underwent four operations. She developed a wound @entity281 and @entity293 during her hospital stay. By the end of hospitalization, the papules followed with coalesce of @entity1066 formed on the previously epithelized areas of her legs. The @entity1 complained of the intensive @entity158 localized on these surfaces. Since @entity6794 was suspected, a dermatologist was included in treatment. Therapy was initiated ( @entity1667 60 mg per day intravenously) with gradual reduction of the dosage. The @entity1 was discharged from hospital two weeks later with almost fully complete cicatrization and epithelization. CONCLUSION: @entity6794 is still difficult to be diagnosed in the absence of specific and sensitive diagnostic methods; however, it is crucial to be suspected as early as possible and to start treatment immediately. Multidisciplinary approach is essential for ontimal results.

title: PYODERMA GANGRENOSUM IN BURNED XXXX - CASE REPORT.

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity6794 :: ('MESH:D017511', 'Disease') :: ['pyoderma gangrenosum', 'Pyoderma gangrenosum']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcerations']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary infection']

answer: @entity1 :: (9606,Species) :: ['PATIENT']


abstract: PURPOSE OF THE STUDY: @entity2067 antagonist treated @entity1 are exposed to a risk of @entity548 in case of @entity1445 leading to a need for transfusion. In order to determine the incidence of adverse transfusion reactions in these @entity1 , the reports indicating a @entity2067 antagonist treatment were analyzed. @entity1 AND METHODS: In the treated and transfused @entity1 population, the diagnosis following the adverse transfusion reactions, the incidence, the degree of severity, the blood component involved and its imputability were evaluated. RESULTS: From January 1st 2000 to December 31st 2014, 142 reports were notified in 141 @entity1 . @entity548 was observed in 102 cases (71.8%). @entity1445 of anti- @entity2067 was reported in 43 cases only (30.3%). The most frequent adverse transfusion reaction was the anti-erythrocyte alloimmunization (66 cases, 46.5%) followed by the febrile non-haemolytic reaction (37 cases, 26.1%). Most adverse reactions were non-severe (131 cases, 92.3%). The most involved blood component was the red blood cells concentrate (139 cases, 97.9%). The imputability of the blood product was certain in 39 cases only (27.5%). CONCLUSION: In @entity1 treated with @entity2067 antagonists and transfused, the anti-erythrocyte alloimmunization was the most frequent adverse transfusion reaction. @entity1445 of the @entity2067 antagonists was notified in approximately a third of cases.

title: [Adverse transfusion reactions in recipients with anti- XXXX treatment].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity1445 :: ('MESH:D062787', 'Disease') :: ['Overdose', 'overdose']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage', 'Haemorrhage']

entities_list: @entity2067 :: ('MESH:D014812', 'Chemical') :: ['Vitamin K', 'vitamin K']

answer: @entity2067 :: (MESH:D014812,Chemical) :: ['vitamin K']


abstract: A retrospective chart review was performed on @entity1 diagnosed as having @entity1737 in @entity16872   State, Brazil and who were followed from October 1981 to June 2009. Clinical and epidemiologic aspects were evaluated. In this work, 122 @entity1 were studied, of whom 85 (69.7%) were females and 37 (30.3%) were males. The disease duration ranged from five months to 50 years (8.9  8.1 years). Age at the first symptoms varied from 0 to 74 years (31.9  14.4 years). The first main symptoms and signs were @entity1736 , @entity892 and @entity425 . Generalized @entity1737 was the most common clinical presentation, but 5.1% (n=6) persisted as @entity1737 . Thymectomy was performed in 42.6% (n=52) of @entity8491 @entity1 . @entity704 was present in 10 patients. Serum @entity934 receptor (AChR) antibodies were present in 80% (n=20) of specimens tested. The data presented are similar to those of studies performed in other countries.

title: XXXX in @entity16872  , Brazil: clinical and epidemiological aspects.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity704 :: ('MESH:D013945', 'Disease') :: ['A thymoma']

entities_list: @entity1737 :: ('MESH:D009157', 'Disease') :: ['myasthenia', 'ocular myasthenia', 'myasthenia gravis']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['limb weakness']

entities_list: @entity8491 :: ('MESH:D020294', 'Disease') :: ['myasthenic']

entities_list: @entity892 :: ('MESH:D004172', 'Disease') :: ['diplopia']

entities_list: @entity934 :: ('MESH:D000109', 'Chemical') :: ['acetylcholine']

answer: @entity1737 :: (MESH:D009157,Disease) :: ['Myasthenia gravis']


abstract: A retrospective chart review was performed on @entity1 diagnosed as having @entity1737 in @entity16872   State, Brazil and who were followed from October 1981 to June 2009. Clinical and epidemiologic aspects were evaluated. In this work, 122 @entity1 were studied, of whom 85 (69.7%) were females and 37 (30.3%) were males. The disease duration ranged from five months to 50 years (8.9  8.1 years). Age at the first symptoms varied from 0 to 74 years (31.9  14.4 years). The first main symptoms and signs were @entity1736 , @entity892 and @entity425 . Generalized @entity1737 was the most common clinical presentation, but 5.1% (n=6) persisted as @entity1737 . Thymectomy was performed in 42.6% (n=52) of @entity8491 @entity1 . @entity704 was present in 10 patients. Serum @entity934 receptor (AChR) antibodies were present in 80% (n=20) of specimens tested. The data presented are similar to those of studies performed in other countries.

title: @entity1737 in XXXX  , Brazil: clinical and epidemiological aspects.

answer: @entity16872 :: (4670,Gene) :: ['Cear']


abstract: Serum lipids, lipoproteins, and more recently apolipoproteins and @entity3452 [ @entity3452 ] have been shown to be independent risk factors for @entity301 and its prognosis. However, the relationships between serum lipid levels and the extent of @entity453 ( @entity453 ) have not been consistently shown. Twenty-five hundred male and female @entity1 with suspected @entity951 were recruited from 18 European medical centers. The independent relations of total @entity165 , @entity1674 , HDL @entity165 , LDL @entity165 , @entity1675 , and @entity3452 with the presence and extent of @entity453 , as assessed by coronary angiography, were investigated. All of the lipid measures showed strong relations P < .0001) with the presence of @entity453 , defined by the existence of at least one > or = 50% @entity3979 . Total @entity165 , LDL @entity165 , apo B, @entity1674 , and @entity3452 were substantially higher and HDL @entity165 and @entity1675 -I lower in @entity1 with @entity453 . The odds ratio of @entity453 , in the high-risk tertile of each lipid's distribution compared with the low-risk tertile, was in the range 1.5 to 2.3. Each of total @entity165 (or LDL @entity165 or apo B), HDL @entity165 (or @entity1675 ), and @entity3452 had an independent effect in predicting the presence of @entity453 . In addition, all lipids showed a strong association (P = .0006 for @entity1674 , P < .0001 otherwise) with the extent of @entity453 as defined by the number of stenosed coronary vessels.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Dose-response relationships of serum lipid measurements with the extent of XXXX . Strong, independent, and comprehensive. ECAT Angina Pectoris Study Group.

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary vessel disease']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity3979 :: ('MESH:D023921', 'Disease') :: ['coronary vessel stenosis']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity3979 :: (MESH:D023921,Disease) :: ['coronary stenosis']


abstract: @entity28 is associated with increased @entity65 and mortality. We hypothesized that microvascular function may be @entity28 with @entity209 (OB-MetSnd) compared to @entity28 subjects without MetSnd (OB) and @entity392 ( @entity392 ). In this cross-sectional study, we evaluated @entity272 ( @entity272 ) in OB-MetSnd (n=20, 12 @entity1 , BMI=36.5  1.1kg/m(2)), OB (n=25, 16 @entity1 , BMI=34.5  0.7kg/m(2)), and @entity392 (n=30, 22 @entity1 , BMI=22.8  0.3kg/m(2)) groups. @entity272 was evaluated by intravital video-microscopy at rest and after post-occlusive reactive @entity450 (PORH) and @entity450 ( @entity450 ). OB-MetSnd subjects exhibited significant differences in the values of MetSnd components and in leptin and HOMA-IR levels compared to OB and @entity392 individuals. There were no differences in @entity272 among groups in resting conditions. The OB-MetSnd group failed to show a significant increase in the number of recruited capillaries during PORH and @entity450 compared to the @entity272 evaluated at rest. A negative correlation of @entity272 with waist circumference, BMI, blood pressure, and HOMA-IR was observed after PORH and @entity450 . When @entity28 subjects were analyzed according to their HOMA-IR quartiles, a significant decrease in @entity272 was observed during POHR (P=0.02). Our findings showed that @entity28 subjects have structural and functional alterations in skin microcirculation that are proportional to the increase in the degree of @entity1144 . In addition, in OB-MetSnd subjects, the cutaneous capillaries at rest are already maximally recruited, indicating an absence of functional capillary reserve. This may be related to the insulin resistance observed in OB-MetSnd individuals.

title: Skin capillary density and microvascular reactivity in XXXX subjects with and without @entity209 .

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['Obesity', 'impaired in obese subjects', 'obese']

entities_list: @entity450 :: ('MESH:D006940', 'Disease') :: ['hyperemia', 'venous congestion', 'VC']

entities_list: @entity1144 :: ('MESH:D056128', 'Disease') :: ['global and central obesity']

entities_list: @entity392 :: ('MESH:D014012', 'Disease') :: ['HS', 'healthy subjects']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin capillary density', 'SCD']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular morbidity']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obese']


abstract: @entity28 is associated with increased @entity65 and mortality. We hypothesized that microvascular function may be @entity28 with @entity209 (OB-MetSnd) compared to @entity28 subjects without MetSnd (OB) and @entity392 ( @entity392 ). In this cross-sectional study, we evaluated @entity272 ( @entity272 ) in OB-MetSnd (n=20, 12 @entity1 , BMI=36.5  1.1kg/m(2)), OB (n=25, 16 @entity1 , BMI=34.5  0.7kg/m(2)), and @entity392 (n=30, 22 @entity1 , BMI=22.8  0.3kg/m(2)) groups. @entity272 was evaluated by intravital video-microscopy at rest and after post-occlusive reactive @entity450 (PORH) and @entity450 ( @entity450 ). OB-MetSnd subjects exhibited significant differences in the values of MetSnd components and in leptin and HOMA-IR levels compared to OB and @entity392 individuals. There were no differences in @entity272 among groups in resting conditions. The OB-MetSnd group failed to show a significant increase in the number of recruited capillaries during PORH and @entity450 compared to the @entity272 evaluated at rest. A negative correlation of @entity272 with waist circumference, BMI, blood pressure, and HOMA-IR was observed after PORH and @entity450 . When @entity28 subjects were analyzed according to their HOMA-IR quartiles, a significant decrease in @entity272 was observed during POHR (P=0.02). Our findings showed that @entity28 subjects have structural and functional alterations in skin microcirculation that are proportional to the increase in the degree of @entity1144 . In addition, in OB-MetSnd subjects, the cutaneous capillaries at rest are already maximally recruited, indicating an absence of functional capillary reserve. This may be related to the insulin resistance observed in OB-MetSnd individuals.

title: Skin capillary density and microvascular reactivity in @entity28 subjects with and without XXXX .

answer: @entity209 :: (MESH:D008659,Disease) :: ['metabolic syndrome']


abstract: Twenty-five @entity1 , aged between 15 and 45 years old, who were athletically active, presented with @entity3331 ( @entity924 ). By use of ultrasonographic examination, new and precise information was obtained that benefited the diagnosis, choice of treatment, and monitoring of the evolution of @entity3331 in our @entity1 . In 18 of the 25 @entity1 , only 1 knee was affected; in 7 of the @entity1 , both knees were affected, thus making a total of 32 @entity158 tendons. These 25 @entity1 were compared with a control group of 15 healthy, athletically active subjects between the ages of 25 and 35 years old. In all of the 32 @entity158 tendons, ultrasonographic anomalies were observed: thickening or swelling of the tendon (15 knees) appeared in acute cases; a heterogeneous structure of the tendon (24 knees); and thickening and irregularities of the tendinous envelope (8 knees). The 15 acute @entity1 all responded to classic conservative treatment including physical therapy and electrotherapy. Four of the remaining 10 @entity1 were treated successfully with various conservative treatments, including deep transverse friction massage with ice. The other six @entity1 were treated surgically, with tenolysis and "carding" of the patellar tendon. In one @entity1 , this procedure failed, and 12 months later a second operation was performed, in which the distal pole of the patella was resected and the patellar tendon reinserted into bone. Recovery was uneventful. Now, at least 2 years after treatment, all of the @entity1 consider themselves healed.

title: XXXX and ultrasonography.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity924 :: ('MESH:D052256', 'Disease') :: ['patellar tendinitis']

entities_list: @entity3331 :: ('MESH:D007718', 'Disease') :: ["jumper's knee"]

answer: @entity3331 :: (MESH:D007718,Disease) :: ['Jumper's knee']


abstract: PURPOSE: To investigate in @entity1538 the focal macular photopic negative response and spectral-domain optical coherence tomography measurements of retinal thicknesses in the superior and inferior macula. DESIGN: Comparative case series. METHODS: We studied 63 eyes of 63 @entity1 with @entity1538 and 41 normal eyes of 41 volunteers. Photopic negative responses were recorded using a spotlight (diameter of 15 degrees of circle), projected onto the whole or superior or inferior macula. Ganglion cell complex (nerve fiber + @entity4494 cell + inner @entity655 ) thickness was measured using spectral-domain optical coherence tomography. RESULTS: Mean photopic negative response amplitude over the entire macula was significantly (P < .001) decreased compared with that of controls in eyes with early (n = 24; to 62.1%), moderate (n = 21; to 57.2%), and severe (n = 18; to 49.3%) @entity1538 , but not significantly different among eyes with various stages of @entity726 . Mean @entity4494 cell complex thickness was significantly (P < .001) decreased compared with that of controls in eyes with early (86.0%), moderate (78.3%), and severe (71.2%) @entity726 , and thinning correlated positively with @entity726 severity (P < .001). Mean photopic negative response amplitude correlated significantly (P < .001) with @entity4494 cell complex thickness over the whole, superior, and inferior macular areas (r = 0.57 to 0.74). In 16 eyes without @entity227 in the inferior hemifield, mean photopic negative response amplitude was 56.5% of normal (P < .001), and mean @entity4494 cell complex thickness in the superior macula was 92.1% of normal (P = .004). CONCLUSIONS: Focal macular photopic negative response amplitude correlates with @entity4494 cell complex thickness, but decreases more abruptly in early @entity726 compared with @entity4494 cell complex thickness.

title: Hemispherical focal macular photopic negative response and macular inner retinal thickness in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual field defect']

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity655 :: ('MESH:C535504', 'Disease') :: ['plexiform layers']

answer: @entity1538 :: (MESH:D005902,Disease) :: ['open-angle glaucoma']


abstract: A new @entity2220 classification is being proposed by the International Association for the Study of @entity2 , American @entity1514 Society and European Respiratory Society (IASLC/ATS/ERS). This proposal has not yet been tested in clinical datasets to determine whether it defines prognostically significant @entity2220 . In all, 514 @entity1 who had pathological @entity5 of the lung classified according to the Union for International @entity5 Control/American Joint Committee on @entity5 7th Edition, and who had undergone a lobectomy with mediastinal lymph node dissection were retrospectively reviewed. Comprehensive histological subtyping was used to estimate the percentage of each histological subtype and to identify the predominant subtype. @entity5 were classified according to the proposed new IASLC/ATS/ERS @entity420 classification. Statistical analyses were made including Kaplan-Meier and Cox regression analyses. There were 323 females (63%) and 191 males (37%) with a median age of 69 years (33-89 years) and 298 stage IA and 216 stage IB @entity1 . Three overall prognostic groups were identified: low grade: @entity420 in situ (n=1) and minimally invasive @entity420 (n=8) had 100% 5-year disease-free survival; intermediate grade: non-mucinous lepidic predominant (n=29), papillary predominant (n=143) and acinar predominant (n=232) with 90, 83 and 84% 5-year disease-free survival, respectively; and high grade: invasive @entity3079 (n=13), colloid predominant (n=9), solid predominant (n=67) and micropapillary predominant (n=12), with 75, 7170 and 67%, 5-year disease-free survival, respectively (P<0.001). Among the clinicopathological factors, stage 1B versus 1A (P<0.001), male sex (P<0.008), high histological grade (P<0.001), vascular invasion (P=0.002) and @entity39 (P<0.001) were poorer prognostic factors on univariate analysis. Both gross @entity5 size (P=0.04) and invasive @entity5 size adjusted by the percentage of lepidic growth (P<0.001) were significantly associated with disease-free survival with a slightly stronger association for the latter. Multivariate analysis showed the prognostic groups of the IASLC/ATS/ERS histological classification (P=0.038), male gender (P=0.007), @entity5 invasive size (P=0.026) and @entity39 (P=0.002) were significant poor prognostic factors. In summary, the proposed IASLC/ATS/ERS classification of @entity2220 identifies histological categories with prognostic differences that may be helpful in identifying candidates for adjunctive therapy. The slightly stronger association with survival for invasive size versus gross size raises the need for further studies to determine whether this adjustment in measuring @entity5 size could impact TNM staging for small @entity420 .

title: Impact of proposed IASLC/ATS/ERS classification of XXXX : prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

entities_list: @entity3079 :: ('MESH:D002288', 'Disease') :: ['mucinous adenocarcinoma']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumors', 'tumor', 'stage I adenocarcinoma', 'Cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['Lung Cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'adenocarcinoma']

entities_list: @entity2220 :: ('MESH:C538231', 'Disease') :: ['subgroups of lung adenocarcinoma', 'lung adenocarcinoma']

answer: @entity2220 :: (MESH:C538231,Disease) :: ['lung adenocarcinoma']


abstract: The effect of the matrix metalloproteinase inhibitor @entity11556 was evaluated in two @entity1 @entity14 models involving: (a) the @entity96 C170HM2 and (b) the lung-invasive @entity5 AP5LV, both of which have been shown to express the M(r) 72,000 type IV collagenase. @entity11556 at concentrations between 0.01 and 3.0 micrograms/ml had no direct cytotoxic effects on the in vitro growth of the cell lines. In the @entity96 model, @entity11556 administered i.p. from day 10 to termination of the therapy (day 39) at 40 mg/kg reduced both the mean number of @entity96 (35% of vehicle-treated control; P < 0.05) and the cross-sectional area of the @entity5 (43% of vehicle-treated control; P < 0.05). In the lung-invasive @entity5 model, @entity11556 administered daily (40 mg/kg i.p.) significantly reduced @entity5 weight within the lung (72% of vehicle-treated control; P < 0.05) but did not significantly affect nodule number. In the latter model, in which the take rate was unaffected, @entity5 cells were introduced into the lateral tail vein, and lung localization may have been a physical phenomenon not involving invasion. In the former model, @entity5 cells were introduced directly into the peritoneal cavity, and from there the cells adhered to and invaded the liver capsule. Because the take rate is significantly reduced, it may be that the matrix metalloproteinases are involved in this process. @entity11556 may be a therapeutic modality for the treatment of @entity14 .

title: Inhibition of organ invasion by the matrix metalloproteinase inhibitor XXXX ( @entity11556 ) in two @entity1 colon carcinoma metastasis models.

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumors', 'liver-invasive tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer metastasis']

entities_list: @entity11556 :: ('MESH:C080985', 'Chemical') :: ['Batimastat', 'batimastat']

answer: @entity11556 :: (MESH:C080985,Chemical) :: ['batimastat']


abstract: The effect of the matrix metalloproteinase inhibitor @entity11556 was evaluated in two @entity1 @entity14 models involving: (a) the @entity96 C170HM2 and (b) the lung-invasive @entity5 AP5LV, both of which have been shown to express the M(r) 72,000 type IV collagenase. @entity11556 at concentrations between 0.01 and 3.0 micrograms/ml had no direct cytotoxic effects on the in vitro growth of the cell lines. In the @entity96 model, @entity11556 administered i.p. from day 10 to termination of the therapy (day 39) at 40 mg/kg reduced both the mean number of @entity96 (35% of vehicle-treated control; P < 0.05) and the cross-sectional area of the @entity5 (43% of vehicle-treated control; P < 0.05). In the lung-invasive @entity5 model, @entity11556 administered daily (40 mg/kg i.p.) significantly reduced @entity5 weight within the lung (72% of vehicle-treated control; P < 0.05) but did not significantly affect nodule number. In the latter model, in which the take rate was unaffected, @entity5 cells were introduced into the lateral tail vein, and lung localization may have been a physical phenomenon not involving invasion. In the former model, @entity5 cells were introduced directly into the peritoneal cavity, and from there the cells adhered to and invaded the liver capsule. Because the take rate is significantly reduced, it may be that the matrix metalloproteinases are involved in this process. @entity11556 may be a therapeutic modality for the treatment of @entity14 .

title: Inhibition of organ invasion by the matrix metalloproteinase inhibitor @entity11556 ( XXXX ) in two @entity1 colon carcinoma metastasis models.

answer: @entity11556 :: (MESH:C080985,Chemical) :: ['BB-94']


abstract: The effect of the matrix metalloproteinase inhibitor @entity11556 was evaluated in two @entity1 @entity14 models involving: (a) the @entity96 C170HM2 and (b) the lung-invasive @entity5 AP5LV, both of which have been shown to express the M(r) 72,000 type IV collagenase. @entity11556 at concentrations between 0.01 and 3.0 micrograms/ml had no direct cytotoxic effects on the in vitro growth of the cell lines. In the @entity96 model, @entity11556 administered i.p. from day 10 to termination of the therapy (day 39) at 40 mg/kg reduced both the mean number of @entity96 (35% of vehicle-treated control; P < 0.05) and the cross-sectional area of the @entity5 (43% of vehicle-treated control; P < 0.05). In the lung-invasive @entity5 model, @entity11556 administered daily (40 mg/kg i.p.) significantly reduced @entity5 weight within the lung (72% of vehicle-treated control; P < 0.05) but did not significantly affect nodule number. In the latter model, in which the take rate was unaffected, @entity5 cells were introduced into the lateral tail vein, and lung localization may have been a physical phenomenon not involving invasion. In the former model, @entity5 cells were introduced directly into the peritoneal cavity, and from there the cells adhered to and invaded the liver capsule. Because the take rate is significantly reduced, it may be that the matrix metalloproteinases are involved in this process. @entity11556 may be a therapeutic modality for the treatment of @entity14 .

title: Inhibition of organ invasion by the matrix metalloproteinase inhibitor @entity11556 ( @entity11556 ) in two XXXX colon carcinoma metastasis models.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: Age 45  years is used as a cutoff in the staging of well-differentiated @entity259 (WDTC) as it represents the median age of most datasets. The aim of this study was to determine a statistically optimized age threshold using a large dataset of @entity1 treated at a comprehensive @entity5 center. METHODS: Overall, 1807 @entity1 with a median follow-up of 109  months were included in the study. Recursive partitioning was used to determine which American Joint Committee on @entity5 (AJCC) variables were most predictive of disease-specific death, and whether a different cutoff for age would be found. From the resulting tree, a new age cutoff was picked and @entity1 were restaged using this new cutoff. RESULTS: The 10-year @entity66 ( @entity66 ) by Union for International @entity5 Control (AJCC/UICC) stage was 99.6, 100, 96, and 81  % for stages I-IV, respectively. Using recursive partitioning, the presence of distant @entity3 was the most powerful predictor of @entity66 . For M0 @entity1 , age was the next most powerful predictor, with a cutoff of 56  years. For M1 @entity1 , a cutoff at 54  years was most predictive. Having reviewed the analysis, age 55  years was selected as a more robust age cutoff than 45  years. The 10-year @entity66 by new stage (using age 55  years as the cutoff) was 99.2, 98, 100, and 74  % for stages I-IV, respectively. CONCLUSION: A change in age cutoff in the AJCC/UICC staging for WDTC to 55  years would improve the accuracy of the system and appropriately prevent low-risk @entity1 being overstaged and overtreated.

title: Defining a Valid Age Cutoff in Staging of Well-Differentiated XXXX .

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['DSS', 'disease-specific survival']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer']

answer: @entity259 :: (MESH:D013964,Disease) :: ['Thyroid Cancer']


abstract: BACKGROUND: Mesenchymal stem cells (MSCs) are multipotent cells residing in the connective tissue of many organs and holding great potential for tissue repair. In culture, @entity1 MSCs (hMSCs) are capable of extensive proliferation without showing chromosomal aberrations. Large numbers of hMSCs can thus be acquired from small samples of easily obtainable tissues like fat and bone marrow. MSCs can contribute to regeneration indirectly by secretion of cytokines or directly by differentiation into specialized cell types. The latter mechanism requires their long-term acceptance by the recipient. Although MSCs do not elicit immune responses in vitro, animal studies have revealed that allogeneic and xenogeneic MSCs are rejected. METHODOLOGY/PRINCIPAL FINDINGS: We aim to overcome MSC immune rejection through permanent down-regulation of major histocompatibility complex (MHC) class I proteins on the surface of these MHC class II-negative cells through the use of viral immune evasion proteins. Transduction of hMSCs with a retroviral vector encoding the @entity4538 @entity73196 protein resulted in strong inhibition of MHC class I surface expression. When transplanted into immunocompetent @entity19 , persistence of the @entity73196 -expressing and HLA-ABC-negative hMSCs at levels resembling those found in immunodeficient (i.e., NOD/ @entity915 ) @entity19 could be attained provided that recipients' natural killer (NK) cells were depleted prior to cell transplantation. CONCLUSIONS/SIGNIFICANCE: Our findings demonstrate the potential utility of herpesviral immunoevasins to prevent rejection of xenogeneic MSCs. The observation that down-regulation of MHC class I surface expression renders hMSCs vulnerable to NK cell recognition and cytolysis implies that multiple viral immune evasion proteins are likely required to make hMSCs non-immunogenic and thereby universally transplantable.

title: Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of XXXX mesenchymal stem cell transplants.

entities_list: @entity4538 :: ('10359', 'Species') :: ['human cytomegalovirus']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: UNASSIGNED: Deregulated expression of the @entity875 ( @entity875 , B, and C) is thought to be involved in cell malignant transformation and genomic instability in several @entity5 types. Over the last decade, a number of small-molecule inhibitors of @entity875 have been developed, which have proved to efficiently restrain malignant cell growth and @entity7433 . Regarding @entity259 ( @entity259 ), we previously showed the efficacy of a pan-Aurora kinase inhibitor ( @entity16513 ) in impairing growth and survival of the @entity259 -derived cell line TT. In the present study, we sought to establish if one of the @entity875 might represent a preferential target for @entity259 therapy. The effects of selective inhibitors of @entity875 ( @entity1890 ) and @entity16511 ( @entity36013 ) were analyzed on TT cell proliferation, apoptosis, cell cycle, and ploidy. The two inhibitors reduced TT cell proliferation in a time- and dose-dependent manner, with IC50 of 19.0      2.4  nM for @entity1890 and 401.6      44.1  nM for @entity36013 . Immunofluorescence experiments confirmed that @entity36013 inhibited phosphorylation of histone H3 (Ser10) by @entity16511 , while it did not affect @entity875 autophosphorylation. @entity1890 inhibited @entity875 autophosphorylation as expected, but at concentrations required to achieve the maximum antiproliferative effects it also abolished H3 (Ser10) phosphorylation. Cytofluorimetry experiments showed that both inhibitors induced accumulation of cells in G2/M phase and increased the subG0/G1 fraction and @entity5700 . Finally, both inhibitors triggered apoptosis. We demonstrated that inhibition of either @entity875 or @entity16511 has antiproliferative effects on TT cells, and thus it would be worthwhile to further investigate the therapeutical potential of Aurora kinase inhibitors in @entity259 treatment.

title: Preclinical testing of selective Aurora kinase inhibitors on a XXXX -derived cell line.

entities_list: @entity5700 :: ('MESH:D011123', 'Disease') :: ['polyploidy']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity7433 :: ('MESH:D002471', 'Disease') :: ['tumorigenicity']

entities_list: @entity875 :: ('6790', 'Gene') :: ['Aurora-A', 'Aurora kinases']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['medullary thyroid carcinoma', 'MTC']

answer: @entity259 :: (MESH:D013964,Disease) :: ['medullary thyroid carcinoma']


abstract: Our aim was to investigate the contribution of variations in intestinal muscle morphology or function to regional differences in motor properties in vivo. We quantitated intestinal muscle thickness and surface area along the @entity235 gut and compared the in vitro contractile properties of the jejunum and ileum. The thickness and cross-sectional surface area of both circular and longitudinal muscle demonstrated a parabolic distribution along the intestine, with the greatest values occurring in the proximal and distal regions. The terminal ileum had the greatest circular (885 +/- 194 microns) and longitudinal muscle (367 +/- 135 microns) thickness. Circular muscle was 2.5-3 times thicker than longitudinal muscle at all points. Passive @entity2701 was similar in muscle strips from the mid-jejunum, mid-ileum, and terminal ileum (2.8 +/- 0.8, 2.5 +/- 0.4, and 2.3 +/- 0.8 vs 2.5 +/- 0.5, 1.9 +/- 0.5, and 2.8 +/- 1.0, longitudinal and circular, respectively). Active and total @entity2701 , however, were significantly greater in longitudinal than circular muscle in mid-jejunum (active; 8.5 +/- 1.4 vs 5.6 +/- 1.2, P < 0.05 and total 11.3 +/- 1.7 vs 8.1 +/- 1.2) and in mid-ileum (active 9.5 +/- 1.6 vs 5.8 +/- 1.2 and total 12.0 +/- 1.6 vs 7.7 +/- 1.2). Values for each layer were similar in both sites. In contrast, in the terminal ileum, longitudinal and circular muscle strips demonstrated similar active (10.1 +/- 1.7 vs 9.0 +/- 2.7, NS) and total @entity2701 (12.4 +/- 2.0 vs 11.9 +/- 3.4, NS). Dose-response curves to @entity5402 (10(-8)-10(-2) M) were similar in all these regions. We conclude (1) there are regional variations in muscle mass but contractile properties are similar in jejunum and ileum; and (2) the unique motor properties of the terminal ileum may be related more to differences in muscle morphology and neural input than intrinsic function.

title: Regional variation in XXXX intestinal muscle mass and function.

entities_list: @entity5402 :: ('MESH:D002217', 'Chemical') :: ['carbachol']

answer: @entity235 :: (9615,Species) :: ['canine']


abstract: Taking into account the wellknown frequency of @entity21 in @entity161 and the rare studies about their evolution, several questions can be raised: How do these different symptoms move? Are there specific characters of each of them? First, stability of negative symptoms evaluated by the Scale for the Assessment of Negative Symptoms ( @entity12269 ) was studied among 57 @entity161 @entity1 at admission and at discharge. The course of negative symptoms was compared to that of @entity308 (Montgomery et Asberg Depression Rating Scale) and @entity2845 symptoms (Extrapyramidal Symptom Rating Scale). All the subscores of the @entity12269 decreased significantly but 4 items belonging to the affective flattening subscale and one item belonging to the @entity2026 subscale did not vary significantly, showing the necessity of taking into account the individual items of the @entity12269 rather than the subscale scores to evaluate the course of negative symptoms. Changes in all the @entity12269 subscores except the @entity2026 and @entity4270 subscores were associated with variations in scores of other scales. Correlations between the changes of negative symptoms and the changes of depressive symptoms showed the necessity to do more specific scales, for example, scales for @entity308 in @entity161 . Langlois-Th  ry et al. (1994) evaluated among 53 @entity161 @entity1 stabilized with neuroleptic treatment, depressive symptomatology with Echelle de Ralentissement D  pressif (ERD, Widl  cher, 1983) and MADRS, negative symptomatology (Positive and Negative Syndrome Scale) and @entity910 (ESRS), to determinate whether ERD composed of 3 subscores (motor, ideic and subjective) could be able to evaluate the depressive symptomatology, independently of the measures of negative and @entity2845 symptomatology.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Depressive symptoms and negative symptoms during XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive MADRS', 'depression']

entities_list: @entity4270 :: ('MESH:D059445', 'Disease') :: ['anhedonia']

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['akinesia']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia', 'schizophrenic']

entities_list: @entity21 :: ('MESH:D001480', 'Disease') :: ['depressive and extrapyramidal symptoms']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: @entity2383 chromosome, especially translocations, are rare events in @entity2590 ( @entity2590 ). In a series of 2270 @entity2590 @entity1 analyzed between 1983 and 1994 (Center for @entity1 Genetics, Leuven), 9 cases were found with translocations involving the X chromosome. These aberrations were not restricted to specific FAB subtypes and were the sole anomalies in 3 cases. In the remaining 6 @entity1 , they were associated with other abnormalities, including 5q-, observed in three cases. Fluorescence in situ hybridization (FISH) was retrospectively performed on 8 @entity1 and was shown to be a useful complement for the characterization of the translocations involving the X chromosome. In 3 cases, we could identify translocation partners and breakpoint regions only by using chromosome painting. No recurrent chromosome partners were observed. The breakpoints could be localized along the whole X chromosome. There was, however, a cluster in the Xq13 region involved in 4 of the 9 @entity1 . The previously reported association of @entity154 with @entity417 with @entity27487 (RARS) was found in only one case. Despite the lack of characteristic translocations involving the X chromosome, the occurrence of such changes as the sole karyotypic anomaly suggests that they could play a role in the pathogenesis of some @entity2590 .

title: Characterization by chromosome painting of balanced and unbalanced X chromosome translocations in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Human']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['Xq13 anomalies']

entities_list: @entity27487 :: ('MESH:D000756', 'Disease') :: ['ringed sideroblasts']

entities_list: @entity417 :: ('MESH:D000740', 'Disease') :: ['refractory anemia']

entities_list: @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndromes', 'MDS']

entities_list: @entity2383 :: ('MESH:D028361', 'Disease') :: ['Structural anomalies of the X']

answer: @entity2590 :: (MESH:D009190,Disease) :: ['myelodysplastic syndromes']


abstract: OBJECTIVE: Our objective was to analyze periprocedural and 1-year outcomes of peripheral endovascular intervention (PVI) for @entity63 ( @entity63 ). METHODS: We reviewed 1244 @entity1 undergoing 1414 PVIs for @entity63 ( @entity158 , 29%; tissue loss, 71%) within the Vascular Study Group of New England (VSGNE) from January 2010 to December 2011. Overall survival (OS), amputation-free survival (AFS), and freedom from major amputation at 1  year were analyzed using the Kaplan-Meier method. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: The number of arteries treated during each procedure were 1 (49%), 2 (35%), 3 (12%), and >= 4 (5%). Target arterial segments and TransAtlantic Inter-Society Consensus classifications were aortoiliac, 27% (A, 48%; B, 28%; C, 12%; and D, 12%); femoral-popliteal, 48% (A, 29%; B, 34%; C, 20%; and D, 17%); and infrapopliteal, 25% (A, 17%; B, 14%; C, 25%; D, 44%). Technical success was 92%. Complications included access site @entity1410 (5.0%), occlusion (0.3%), and distal embolization (2.4%). Mortality and major amputation rates were 2.8% and 2.2% at 30  days, respectively. Overall percutaneous or open reintervention rate was 8.0% during the first year. At 1-year, OS, AFS, and freedom from major amputation were 87%, 87%, and 94% for @entity1 with @entity158 and 80%, 71%, and 81% for @entity1 with tissue loss. Independent predictors of reduced 1-year OS (C index  = .74) included dialysis (HR, 3.8; 95% CI, 2.8-5.1; P  < .01), emergency procedure (HR, 2.5; 95% CI, 1.0-6.2; P  = .05), age >80  years (HR, 2.2; 95% CI, 1.7-2.8; P  < .01), not living at home preoperatively (HR, 2.0; 95% CI, 1.4-2.8; P  < .01), @entity1011 >1.8  mg/dL (HR, 1.9; 95% CI, 1.3-2.8; P  < .01), @entity712 (HR, 1.7; 95% CI, 1.3-2.2; P  < .01), and chronic b-blocker use (HR, 1.4; 95% CI, 1.0-1.9; P  = .03), whereas independent preoperative ambulation (HR, 0.7; 95% CI, 0.6-0.9; P  = .014) was protective. Independent predictors of major amputation (C  index  = .69) at 1  year included dialysis (HR, 2.7; 95% CI, 1.6-4.5; P  < .01), tissue loss (HR, 2.0; 95% CI, 1.1-3.7; P  = .02), prior major contralateral amputation (HR, 2.0; 95% CI, 1.1-3.5; P  = .02), non-Caucasian race (HR, 1.7; 95% CI, 1.0-2.9; P  = .045), and male gender (HR, 1.6; 95% CI, 1.1-2.6; P  = .03), whereas smoking (HR, .60; 95% CI, 0.4-1.0; P  = .042) was protective. CONCLUSIONS: Survival and major amputation after PVI for @entity63 are associated with different @entity1 characteristics. @entity734 is a common predictor that portends especially poor outcomes. These data may facilitate efforts to improve @entity1 selection and, after further validation, enable risk-adjusted outcome reporting for @entity63 @entity1 undergoing PVI.

title: Determinants of survival and major amputation after peripheral endovascular intervention for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['critical limb ischemia', 'CLI']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['rest pain']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['Dialysis dependence']

answer: @entity63 :: (MESH:D007511,Disease) :: ['critical limb ischemia']


abstract: The adult subventricular zone (SVZ) of the lateral ventricle contains neural stem cells. In rodents, these cells generate neuroblasts that migrate as chains toward the olfactory bulb along the rostral migratory stream (RMS). The neural-stem-cell niche at the ventricular wall is conserved in various animal species, including primates. However, it is unclear how the SVZ and RMS organization in nonhuman primates relates to that of rodents and @entity1 . Here we studied the SVZ and RMS of the adult and neonatal @entity7533 ( @entity7533 ), a New World primate used widely in neuroscience, by electron microscopy, and immunohistochemical detection of cell-type-specific markers. The marmoset SVZ contained cells similar to type B, C, and A cells of the rodent SVZ in their marker expression and morphology. The adult marmoset SVZ had a three-layer organization, as in the @entity1 brain, with ependymal, hypocellular, and astrocyte-ribbon layers. However, the hypocellular layer was very thin or absent in the adult-anterior and neonatal SVZ. Anti-PSA-NCAM staining of the anterior SVZ in whole-mount ventricular wall preparations of adult marmosets revealed an extensive network of elongated cell aggregates similar to the neuroblast chains in rodents. Time-lapse recordings of marmoset SVZ explants cultured in Matrigel showed the neuroblasts migrating in chains, like rodent type A cells. These results suggest that some features of neurogenesis and neuronal migration in the SVZ are common to marmosets, @entity1 , and rodents. This basic description of the adult and neonatal marmoset SVZ will be useful for future studies on adult neurogenesis in primates.

title: Cellular composition and organization of the subventricular zone and rostral migratory stream in the adult and neonatal XXXX brain.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human']

entities_list: @entity7533 :: ('9483', 'Species') :: ['Callithrix jacchus', 'common marmoset']

answer: @entity7533 :: (9483,Species) :: ['common marmoset']


abstract: BACKGROUND: The 595-nm pulsed dye laser has been used for the treatment of benign epidermal @entity66 (EPLs), but there is a risk of inducing undesirable purpura with treatment. OBJECTIVE: To compare a 607-nm laser with a commercially-available 595-nm laser for the treatment of EPLs. MATERIALS AND METHODS: Monte-Carlo simulations were performed to characterize laser interaction with skin. Ten @entity1 with EPLs were treated with a 607-nm study prototype laser and the 595-nm pulsed dye laser twice at 2- to 4-week intervals on the left or right side on a randomized basis. Study endpoints included clearance rate of lesions, side effects immediately after treatment and at final follow-up, and @entity1 discomfort/ @entity158 . RESULTS: Monte-Carlo simulations show that the 607-nm is absorbed more specifically by melanin than the 595-nm wavelength. Both lasers were effective in treatment of EPLs. The average degree of improvement overall was 41.2% with the 607-nm laser and 40% with the 595-nm laser. @entity1 reported less discomfort/ @entity158 during treatment with the 607-nm laser. CONCLUSIONS: Our findings suggest that the 607-nm laser is safe and at least as effective as the 595-nm laser in treatment of EPLs. There was less @entity1 discomfort/ @entity158 during treatment using the 607-nm laser.

title: Pulsed dye laser treatment of XXXX : a randomized clinical pilot study comparison of 607- and 595-nm wavelength lasers.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['pigmented lesions']

answer: @entity66 :: (MESH:D004194,Disease) :: ['pigmented lesions']


abstract: We have undertaken a prospective study of @entity130 due to coitus with the aim of evaluating their incidence, risk factors and anatomic lesions. Over a period of 39 months, 98 cases were found, giving a monthly incidence of 2.5. The @entity1 had a mean age of 25 years, were paucipara in more than 50%. Sexual abstience was found in 72 cases with a mean duration of 6 months. This injury occurred more often in gynecological period than in the postpartum (77 cases versus 22). During sexual intercourse the most harmful position was when the @entity1 was in dorsal decubitus with maximum flexion and abduction of the limbs. The @entity130 was located in the posterior cul de sac in 39 cases and was of 5 cm of length in 56%. Surgical suture was required in 92 out of 98 @entity1 , in combination with local and general antibiotics. CONCLUSION: @entity130 due to coitus are frequent in our practice and they create serious anatomic lesions. So there is a need to precise the etiopathogenicity ( @entity2338 ?, infections ?, role of the male partner) and to evaluate the long term sequellas.

title: [ XXXX during coitus: 98 cases].

entities_list: @entity2338 :: ('MESH:D004393', 'Disease') :: ['hormonal deficiency']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['vaginal injury', 'Vaginal injuries', 'vaginal injuries']

answer: @entity130 :: (MESH:D014947,Disease) :: ['Vaginal injuries']


abstract: A 36-year-old asymptomatic Chinese male with @entity8 ( @entity8 ) developed @entity101 1 year after the diagnosis of @entity8 . The @entity1 was treated initially as for @entity101 associated with @entity8 . However, over a 6-year period his @entity101 became progressively difficult to control and he developed severe symptomatic @entity1371 . Subsequent investigations confirmed the presence of primary @entity1368 . The initial computed tomographic scans of the adrenals did not reveal any definite @entity652 . The @entity1 subsequently underwent bilateral adrenal venous sampling, which suggested a left-sided source of @entity1369 excess. A repeat computed tomography of the adrenals with fine cuts revealed a 6-mm diameter adenoma of the left adrenal gland. He underwent an uncomplicated left adrenalectomy. All antihypertensive and @entity972 supplements were stopped on the 5th postoperative day. Two and half years after the adrenalectomy he remains normotensive and normokalaemic without any medication. The case illustrates the importance of measuring serum @entity972 before initiation of any therapy and the need to consider secondary causes even if a primary association is known. It also reinforces the fact that when @entity101 becomes difficult to control, a secondary cause has to be searched actively. The association between @entity1368 and @entity8 has been highlighted only recently. The association of @entity8767 and @entity1368 has been reported in the literature only once previously.

title: XXXX in disguise--a trap for the unwary.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['PKD', 'polycystic kidney disease', 'renal cysts']

entities_list: @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity8767 :: ('MESH:D007690', 'Disease') :: ['polycystic kidneys']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas']

entities_list: @entity1368 :: ('MESH:D006929', 'Disease') :: ['hyperaldosteronism', 'primary aldosteronism']

entities_list: @entity1371 :: ('MESH:D007008', 'Disease') :: ['hypokalemia']

answer: @entity101 :: (MESH:D006973,Disease) :: ['Hypertension']


abstract: PURPOSE: To evaluate the use of a slow-release @entity619 0.7-mg intravitreal implant for @entity1103 ( @entity1103 ) secondary to intermediate @entity1596 and refractory to systemic @entity230 . METHODS: A retrospective study of the best-corrected visual acuity (BCVA), @entity32 , intraocular pressure (IOP), fundus photography, optical coherence tomography (OCT), @entity32 , and adverse reactions of five @entity1 ( @entity1 , mean age of 35 years) with @entity1103 treated with a @entity619 implant. @entity1 were evaluated in seven visits until the 150th day after the implant. RESULTS: Four @entity1 had bilateral pars @entity2038 and one had bilateral intermediate @entity1596 associated with @entity4932 . Six @entity619 devices were implanted, under topical anesthesia (one each in six eyes, five @entity1 ). The mean follow-up time was 5 months. The best-corrected visual acuity improved in all eyes that received an implant, with five having improvements of two or more lines. Optical coherence tomography showed thinning of the macula in all eyes treated, and we saw a correlation between the best-corrected visual acuity and retinal thinning. No serious adverse events occurred and no significant increase in intraocular pressure was observed. CONCLUSIONS: Slow-release @entity619 intravitreal implants can effectively treat @entity1103 secondary to intermediate @entity1596 and refractory to systemic @entity230 .

title: Treatment of @entity1103 secondary to chronic non-infectious intermediate XXXX with an intraocular @entity619 implant.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['intraocular inflammation', 'inflammation']

entities_list: @entity1103 :: ('MESH:D008269', 'Disease') :: ['CME', 'cystoid macular edema']

entities_list: @entity4932 :: ('MESH:D001171', 'Disease') :: ['juvenile idiopathic arthritis']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity1596 :: (MESH:D014605,Disease) :: ['uveitis']


abstract: PURPOSE: To evaluate the use of a slow-release @entity619 0.7-mg intravitreal implant for @entity1103 ( @entity1103 ) secondary to intermediate @entity1596 and refractory to systemic @entity230 . METHODS: A retrospective study of the best-corrected visual acuity (BCVA), @entity32 , intraocular pressure (IOP), fundus photography, optical coherence tomography (OCT), @entity32 , and adverse reactions of five @entity1 ( @entity1 , mean age of 35 years) with @entity1103 treated with a @entity619 implant. @entity1 were evaluated in seven visits until the 150th day after the implant. RESULTS: Four @entity1 had bilateral pars @entity2038 and one had bilateral intermediate @entity1596 associated with @entity4932 . Six @entity619 devices were implanted, under topical anesthesia (one each in six eyes, five @entity1 ). The mean follow-up time was 5 months. The best-corrected visual acuity improved in all eyes that received an implant, with five having improvements of two or more lines. Optical coherence tomography showed thinning of the macula in all eyes treated, and we saw a correlation between the best-corrected visual acuity and retinal thinning. No serious adverse events occurred and no significant increase in intraocular pressure was observed. CONCLUSIONS: Slow-release @entity619 intravitreal implants can effectively treat @entity1103 secondary to intermediate @entity1596 and refractory to systemic @entity230 .

title: Treatment of @entity1103 secondary to chronic non-infectious intermediate @entity1596 with an intraocular XXXX implant.

answer: @entity619 :: (MESH:D003907,Chemical) :: ['dexamethasone']


abstract: PURPOSE: To evaluate the use of a slow-release @entity619 0.7-mg intravitreal implant for @entity1103 ( @entity1103 ) secondary to intermediate @entity1596 and refractory to systemic @entity230 . METHODS: A retrospective study of the best-corrected visual acuity (BCVA), @entity32 , intraocular pressure (IOP), fundus photography, optical coherence tomography (OCT), @entity32 , and adverse reactions of five @entity1 ( @entity1 , mean age of 35 years) with @entity1103 treated with a @entity619 implant. @entity1 were evaluated in seven visits until the 150th day after the implant. RESULTS: Four @entity1 had bilateral pars @entity2038 and one had bilateral intermediate @entity1596 associated with @entity4932 . Six @entity619 devices were implanted, under topical anesthesia (one each in six eyes, five @entity1 ). The mean follow-up time was 5 months. The best-corrected visual acuity improved in all eyes that received an implant, with five having improvements of two or more lines. Optical coherence tomography showed thinning of the macula in all eyes treated, and we saw a correlation between the best-corrected visual acuity and retinal thinning. No serious adverse events occurred and no significant increase in intraocular pressure was observed. CONCLUSIONS: Slow-release @entity619 intravitreal implants can effectively treat @entity1103 secondary to intermediate @entity1596 and refractory to systemic @entity230 .

title: Treatment of XXXX secondary to chronic non-infectious intermediate @entity1596 with an intraocular @entity619 implant.

answer: @entity1103 :: (MESH:D008269,Disease) :: ['cystoid macular edema']


abstract: BACKGROUND: @entity4499 are a major complication following percutaneous cannulations of the femoral artery. Surgical repair has been the traditional treatment modality. Recent reports have introduced duplex-guided compression as a means of nonoperative management of these injuries. We proposed to determine if duplex-guided compression of @entity2096 could be successfully performed, could be done without complication, and could maintain @entity715 on long-term follow-up. STUDY DESIGN: All @entity1 presenting with large groin @entity1410 following invasive percutaneous femoral artery procedures over a seven-month period were studied using color-flow duplex analysis. Six @entity2849 were discovered and successfully treated with duplex-guided compression. All @entity1 were then followed-up prospectively with both early and long-term repeat duplex analysis. RESULTS: All @entity1 were rescanned 72 hours later and the @entity2849 remained @entity715 . Upon returning for long-term follow-up examination, @entity1 again had duplex confirmation of @entity715 , with a mean follow-up time of 21 months (range, five to 29 months). No complications attributable to this technique have been noted. CONCLUSIONS: This study confirms the clinical usefulness of duplex-guided compression in the evaluation and treatment of iatrogenic @entity2096 .

title: Duplex-guided compression of iatrogenic XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4499 :: ('MESH:D007049', 'Disease') :: ['Iatrogenic pseudoaneurysms']

entities_list: @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematomas']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosed', 'thrombosis']

entities_list: @entity2096 :: ('MESH:D020428', 'Disease') :: ['femoral pseudoaneurysms']

entities_list: @entity2849 :: ('MESH:D017541', 'Disease') :: ['pseudoaneurysms']

answer: @entity2096 :: (MESH:D020428,Disease) :: ['femoral pseudoaneurysms']